Journal List > Nat Prod Sci > v.22(2) > 1060606

TOOLS
Park, Lee, Lee, Jang, Jin, Lee, and Hwang: Chemical Constituents from Buddleja officinalis and Their Inhibitory Effects on Nitric Oxide Production
Original Article

Natural Product Sciences 2016;22(2):129-133.

Published online: 17 December 2016

DOI: https://doi.org/10.20307/nps.2016.22.2.129

Chemical Constituents from Buddleja officinalis and Their Inhibitory Effects on Nitric Oxide Production

Tae Wook Park, Chul Lee, Jin Woo Lee, Hari Jang, Qinghao Jin, Mi Kyeong Lee, Bang Yeon Hwang∗

College of Pharmacy, Chungbuk National University, Cheongju 28644, Korea

∗Author for correspondence Bang Yeon Hwang, ollege of Pharmacy, Chungbuk National University, Cheongju 28644, Korea Tel: +82-43-261-2814; E-mail: byhwang@chungbuk.ac.kr

Received 29 December 2015       Revised 28 January 2016       Accepted 28 January 2016

Copyright © 2016 The Korean Society of Pharmacognosy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Bioactivity-guided fractionation of a methanolic extract of Buddleja officinalis led to the isolation of two monoterpenes, crocusatin M (1), crocusatin C (2), a flavonoid, acacetin (3), three lignans, lariciresinol (4), pinoresinol (5), and syringaresinol (6), and two triterpenoidal saponins, mimengoside B (7) and songarosaponin A (8). The structures of isolates were identified based on 1D-, 2D-NMR, and MS data analysis. All isolates were tested for their inhibition on LPS-induced NO production in RAW 264.7 cells. As a result, mimengoside B (7) and songarosaponin A (8) showed a mild inhibitory activity of NO production.

Keywords: Buddleja officinalis, Buddlejaceae, NO production inhibitor

REFERENCES

(1). Tang W., Eisenbrand G.Handbook of Chinese Medicinal Plants; Wiley-VCH: Germany. 2011; 267–270.
(2). Houghton P. J., Mensah A. Y., Iessa N., Hong L. Y.Phytochemistry. 2003; 64:385–393.
crossref
(3). Tai B. H., Nhiem N. X., Quang T. H., Ngan N. T., Tung N. H., Kim Y., Lee J. J., Myung C. S., Cuong N. M., Kim Y. H.Bioorg. Med. Chem. Lett. 2011; 21:3462–3466.
(4). Tai B. H., Jung B. Y., Cuong N. M., Linh P. T., Tung N. H., Nhiem N. X., Huong T. T., Anh N. T., Kim J. A., Kim S. K., Kim Y. H.Biol. Pharm. Bull. 2009; 32:1952–1956.
(5). Guo H., Koike K., Li W., Satou T., Guo D., Nikaido T. J.Nat. Prod. 2004; 67:10–13.
(6). Piao M. S., Kim M. R., Lee D. G., Park Y., Hahm K. S., Moon Y. H., Woo E. R.Arch. Pharm. Res. 2003; 26:453–457.
(7). Liao Y. H., Houghton P. J., Hoult J. R. J.Nat. Prod. 1999; 62:1241–1245.
(8). Lee C., Lee S., Park S. Y.Nat. Prod. Sci. 2013; 19:355–359.
(9). Li C. Y., Wu T. S.Chem. Pharm. Bull. 2002; 50:1305–1309.
(10). Yim S. H., Kim H. J., Lee I. S.Arch. Pharm. Res. 2003; 26:128–131.
(11). Lee D. Y., Song M. C., Yoo K. H., Bang M. H., Chung I. S., Kim S. H., Kim D. K., Kwon B. M., Jeong T. S., Park M. H., Baek N. I.Arch. Pharm. Res. 2007; 30:402–407.
(12). Kwon H. C., Choi S. U., Lee J. O., Bae K. H., Zee O. P., Lee K. R.Arch. Pharm. Res. 1999; 22:417–422.
(13). Emam A. M., Moussa A. M., Faure R., Elias R., Balansard G. J.Ethnopharmacol. 1997; 58:215–217. 1992.
(14). Ding N., Yahara S., Nohara T.Chem. Pharm. Bull. 1992; 40:780–782.
(15). Seifert K., Preiss A., Johne S., Schmidt J., Lien N. T., Lavaud C., Massiot G.Phytochemistry. 1991; 30:3395–3400.
(16). Tundis R., Bonesi M., Deguin B., Loizzo M. R., Menichini F., Conforti F., Tillequin F., Menichini F.Bioorg. Med. Chem. 2009; 17:4542–4547.
(17). Jung H. J., Kim S. G., Nam J. H., Park K. K., Chung W. Y., Kim W. B., Lee K. T., Won J. H., Choi J. W., Park H. J.Biol. Pharm. Bull. 2005; 28:1668–1671.
(18). Won J. H., Im H. T., Kim Y. H., Yun K. J., Park H. J., Choi J. W., Lee K. T. Br. J.Pharmacol. 2006; 148:216–225.
(19). Oh W. J., Jung U., Eom H. S., Shin H. J., Park H. R.Molecules. 2013; 18:9195–9206.

Fig. 1.
Structures of 1–8 isolated from B. officinalis.
nps-22-129f1.tif
Table 1.
13 C NMR data of compounds 7 and 8 (δ in ppm, 125MHz, CD3 OD)a
Position 7 8 position 7 8
1 40.6 39.6 Fuc 1 104.5 105.3
2 26.6 27.0 2 76.7 77.3
3 84.2 86.2 3 85.5 84.9
4 44.3 44.9 4 72.2 72.9
5 49.7 49.2 5 71.2 71.8
6 17.8 17.8 6 17.7 17.4
7 33.5 31.3 Glc 1 105.0 105.7
8 42.8 41.4 2 75.2 75.3
9 54.1 56.2 3 79.2 79.8
10 37.9 36.5 4 72.1 72.8
11 76.2 127.7 5 76.6 76.9
12 122.7 127.0 6 61.6 62.2
13 150.5 138.1 Glc' 1 103.4 104.0
14 44.4 43.9 2 76.2 76.0
15 33.6 32.4 3 77.5 77.3
16 22.7 25.3 4 78.2 78.8
17 38.7 42.0 5 75.9 76.6
18 43.3 136.5 6 63.4 64.1
19 47.4 37.9 Rha 1 102.7 103.4
20 32.0 33.3 2 72.6 73.2
21 31.7 34.2 3 72.3 73.0
22 26.7 30.2 4 73.6 74.3
23 64.6 64.2 5 70.5 71.2
24 13.0 13.2 6 18.6 18.4
25 16.7 18.4      
26 18.8 19.4      
27 25.5 19.4      
28 69.6 65.1      
29 35.1 34.2      
30 23.8 24.5      
-OCH3 53.2        

a The assignments were based on 1H-1H COSY, HMQC, and HMBC experiments.

Table 2.
Inhibitory effects of compounds 1–8 on LPS-induced NO production
compound IC50 (μ M)a
crocusatin M (1) >50
crocusatin C (2) >50
acacetin (3) >50
lariciresinol (4) >50
pinoresinol (5) >50
syringaresinol (6) >50
mimengoside B (7) 22.1 ± 0.8
songarosaponin A (8) 25.6 ± 1.0
aminoguanidineb 17.5 ± 0.7

a Results are expressed as means ± SD from triplicate experiments.

b Positive control.

TOOLS
Similar articles